Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. - Wikidata - wikimedia - TriplyDB

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

http://www.wikidata.org/entity/Q30843979

about

Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab Targeted therapies in CLL: mechanisms of resistance and strategies for management The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.Building better monoclonal antibody-based therapeutics.Germline mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia.Processing of complex N-glycans in IgG Fc-region is affected by core fucosylation Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.Chronic lymphocytic leukemia therapy: new targeted therapies on the way New Pharmacotherapies in Chronic Lymphocytic Leukemia.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial.Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.Obinutuzumab in chronic lymphocytic leukemia.Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.Chronic lymphocytic leukemia (CLL)-Then and now.Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.Recent advances in therapy of chronic lymphocytic leukaemia.How I manage ibrutinib-refractory chronic lymphocytic leukemia.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.

P2860

Q26773135-AD617661-5B88-46FD-BAE1-CE4AAC4CD58D Q26796455-BBA23124-ECC6-4D2E-A114-EB805786774C Q26801292-0907955D-4011-44D8-9BF9-3AAD8298DB24 Q27002528-CEC57372-C7D1-432B-986D-43CBF140978D Q28075504-86851F69-EB92-4348-BC6F-69561C0B331A Q28082086-84C51C71-4BEE-4C60-BACF-D35DE1DD4A7A Q33418091-7C5DB7E4-8AA8-408B-B88B-372DE149F2B9 Q33626106-A6109B17-9677-4052-80D0-3D24FEF7B32B Q33780903-8C7DEBBD-9D88-4784-90A9-58E062EB4731 Q35076449-CEDFE7F0-4968-408F-8452-75D6FA64B6FE Q35110582-F0C49EE7-098C-4AA4-93FB-D740CE93C586 Q35817552-1B076A89-14BC-4D11-8465-1795079F1889 Q36104721-A1C2397B-D840-47D0-A060-C1CEA6019747 Q36211489-F44EE6E1-8799-422C-BC96-36874D45FE86 Q36443141-D0162FEB-99FC-4A81-8E45-24C7C95BFAFE Q36826893-A2A872F5-188D-4042-8A24-650F028103BA Q36998859-9750408E-30C6-44D2-956C-1A3B98594FD4 Q37113544-D066DD13-E0C4-4BE5-824C-D117DFEF4118 Q37605306-6F25C60F-B6A1-4E14-B83E-C01F4613296F Q37672472-481E9511-530F-4684-8A31-90627C9D9832 Q38283828-22EA454B-C64D-4451-B902-0CEC071477C4 Q38317353-6B97444A-B991-4B12-BBEC-9A4DF858CEDA Q38524270-78BE4F6B-D1D6-4A9A-88C2-EC4FF1AC927F Q38537523-984B9A96-92FF-4AF7-9027-4D29935B841E Q38569094-0B9402A4-74D5-405B-8439-D95EBB80A031 Q38573785-9979273B-E934-46D3-8F2B-C85554025530 Q38586543-BF9BE005-8FF1-4763-BE1B-11642FD98011 Q38601727-AAE78BB7-EE4D-41F0-BAAD-4E2EAFDDDD00 Q38646074-81E4AD7B-A6E9-47D9-B32B-E93A2F585693 Q38675358-16347FAC-FFEF-4EDA-B94E-D85616D1A418 Q38693748-5592E396-D824-489C-B8A5-039D4D971A3E Q38744632-61EEF87B-552D-4984-89FF-6E496297F1FA Q38759420-9155E026-E42A-45B9-A80A-8784F05A393A Q38759754-3BD0B318-9C84-4A2C-8CEB-E60D89E064E3 Q38770131-39B2BCE9-16D2-415B-9BA8-74B6F0D68DDF Q38818283-EEC9052F-BD4D-4031-8F5E-2584180936FE Q38824182-30A35FB2-7330-4ECA-BA31-3FE571509B4B Q38862525-BE33A527-0232-4E3D-B0C2-A5F2B20E6BB3 Q39016282-FC448DF7-48CA-4660-9432-98682FD39DF0 Q39018189-64C51334-AF98-4C4C-BE12-CBEEC51309B1

P2860

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

http://www.wikidata.org/entity/Q30843979

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Obinutuzumab (GA101) in relaps ...... m the phase 1/2 GAUGUIN study.

@ast

Obinutuzumab (GA101) in relaps ...... m the phase 1/2 GAUGUIN study.

@en

type

label

Obinutuzumab (GA101) in relaps ...... m the phase 1/2 GAUGUIN study.

@ast

Obinutuzumab (GA101) in relaps ...... m the phase 1/2 GAUGUIN study.

@en

prefLabel

Obinutuzumab (GA101) in relaps ...... m the phase 1/2 GAUGUIN study.

@ast

Obinutuzumab (GA101) in relaps ...... m the phase 1/2 GAUGUIN study.

@en

P1433

Q30843979-8C924390-FF10-4E15-BAE4-FBDBC7773118

P1476

Q30843979-D4D7A419-2FAF-4EBD-AE7D-2FE03015B81B

P2093

Q30843979-027E825E-E9F2-472D-909C-FF70BDEAB530

Q30843979-07F1D92B-BDC2-4AD9-A65F-B231884408E4

Q30843979-11F36197-AD17-4739-BA60-E86A08DC5727

Q30843979-735B7279-6245-4E37-942A-569CB58059AB

Q30843979-8B8087D4-E30F-421A-8ACF-A09857CB1B23

Q30843979-981F2783-0BC1-4C0E-B5A1-D15925C592D9

Q30843979-B8313B45-1796-4F62-9ED9-BCDFFA211FF9

Q30843979-C0EE3FF9-5FE6-47C5-AC23-F87C844F6C68

Q30843979-C6BDE19B-861D-41B3-B1B1-026820888A89

Q30843979-D27B5647-4020-4728-BCA3-1389D24A1678

P304

Q30843979-23A264AA-B93A-493C-A30D-5E52BF9C1A41

P31

Q30843979-309F2BF3-F2BA-40C0-AFE2-898514EE4EE1

P356

Q30843979-8A8598DB-41AE-4FDC-A024-1F0011C1A6EF

P407

Q30843979-A991FFBD-17DB-4339-8BB3-E7DF32C49271

P433

Q30843979-8F10BA86-2FF0-421F-9A52-E1E983151B0F

P478

Q30843979-8E080D46-76CD-4D19-BCA8-172A5602D643

P50

Q30843979-2578C37D-EC5C-41D2-9689-67F8272C8DA8

Q30843979-2926F42A-2CEC-424A-AF04-9928A2B49C22

P577

Q30843979-0724DFBE-008E-4980-B3EA-1381A127E8BE

P698

Q30843979-D18F5FEE-799F-45B9-A61E-DC8B9C6AD105

P921

Q30843979-8694FEAF-789B-43A4-8695-7D4F37F23193

Q30843979-C2856A17-1EB1-4D93-9559-B4806427E5BF

P356

BLOOD-2014-07-586610

P1433

P1476

Obinutuzumab (GA101) in relaps ...... m the phase 1/2 GAUGUIN study.

@en

P2093

Beatrice Mahe

http://www.w3.org/2001/XMLSchema#string

Elisabeth Wassner-Fritsch

http://www.w3.org/2001/XMLSchema#string

Franck Morschhauser

http://www.w3.org/2001/XMLSchema#string

Guiyuan Lei

http://www.w3.org/2001/XMLSchema#string

Jehan Dupuis

http://www.w3.org/2001/XMLSchema#string

Marie-Sarah Dilhuydy

http://www.w3.org/2001/XMLSchema#string

Michael Wenger

http://www.w3.org/2001/XMLSchema#string

Reda Bouabdallah

http://www.w3.org/2001/XMLSchema#string

Sophie de Guibert

http://www.w3.org/2001/XMLSchema#string

Veronique Leblond

http://www.w3.org/2001/XMLSchema#string

P304

2196-2202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-07-586610

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Guillaume Cartron

P577

2014-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25143487

http://www.w3.org/2001/XMLSchema#string

P921